2023
131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML
Choe H, Tomlinson B, Gyurkocza B, Nath R, Seropian S, Litzow M, Abboud C, Stiff P, Abhyankar S, Foran J, Abedin S, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Magalhaes-Silverman M, Van Besien K, Schuster M, Law A, Mayer S, Lazarus H, Spross J, Li K, Haeuber E, Vusirikala M, Nahar A, Sandmaier B, Pagel J, Giralt S, Desai A, Koshy N. 131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML. Blood 2023, 142: 469. DOI: 10.1182/blood-2023-182177.Peer-Reviewed Original ResearchMedian overall survivalAllogeneic hematopoietic cell transplantDurable complete remissionHematopoietic cell transplantOverall survivalR AMLConventional careTP53 mutationsPositive ptsCC groupComplete remissionRelapse rateCell transplantHigh post-transplant relapse ratesInitiation of therapyPhase 3 studyTotal body irradiationHigh relapse rateCRP assessmentEvaluable ptsOlder ptsActive diseaseBaseline characteristicsRefractory AMLBody irradiation
2021
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant
Bewersdorf JP, Derkach A, Gowda L, Menghrajani K, DeWolf S, Ruiz JD, Ponce DM, Shaffer BC, Tamari R, Young JW, Jakubowski AA, Gyurkocza B, Chan A, Xiao W, Glass J, King AC, Cai SF, Daniyan A, Famulare C, Cuello BM, Podoltsev NA, Roshal M, Giralt S, Perales MA, Seropian S, Cho C, Zeidan AM, Prebet T, Stein EM, Tallman MS, Goldberg AD, Stahl M. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Leukemia & Lymphoma 2021, 62: 3394-3401. PMID: 34477024, PMCID: PMC9012492, DOI: 10.1080/10428194.2021.1966788.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaAllogeneic hematopoietic cell transplantAllo-HCTHematopoietic cell transplantSalvage therapyMyelodysplastic syndromeCell transplantMemorial Sloan-Kettering Cancer CenterHigh-risk myelodysplastic syndromeSecond allo-HCTSalvage treatment optionOverall response rateMedian followMedian OSVenetoclax therapyRetrospective studyCancer CenterTreatment optionsOS estimatesMyeloid leukemiaPatientsResponse rateTherapyTransplantMonths575 Application of Pharmacogenomic Guided Immunosuppression Dosing in Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
Perreault S, Schiffer M, Gowda L, Foss F, Isufi I, Seropian S. 575 Application of Pharmacogenomic Guided Immunosuppression Dosing in Allogeneic Hematopoietic Stem Cell Transplant (HSCT). Transplantation And Cellular Therapy 2021, 27: s461. DOI: 10.1016/s2666-6367(21)00600-x.Peer-Reviewed Original Research
2020
Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved
Shallis RM, Gale RP, Lazarus HM, Roberts KB, Xu ML, Seropian SE, Gore SD, Podoltsev NA. Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved. Blood Reviews 2020, 47: 100773. PMID: 33213985, DOI: 10.1016/j.blre.2020.100773.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyeloid sarcomaAllogeneic hematopoietic cell transplantWorld Health Organization classificationAcute myeloid leukemia tumorsLeukemia tumorsOutcomes of patientsPost-remission therapyHematopoietic cell transplantMedian latency periodIndependent prognostic impactBone marrow evaluationAnti-leukemia therapyPET/CTCellular adhesion moleculesPatient characteristicsPrognostic impactLocal therapyCell transplantMarrow evaluationOrganization classificationConventional chemotherapyMyeloid leukemiaTherapeutic approachesReceptor/ligandClinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*
Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*. Leukemia & Lymphoma 2020, 61: 2180-2190. PMID: 32362171, PMCID: PMC7603787, DOI: 10.1080/10428194.2020.1759051.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMedian overall survivalTherapy-related malignanciesOverall survivalMyelodysplastic syndromeMyeloid leukemiaAllogeneic hematopoietic stem cell transplantLonger median overall survivalSingle-center retrospective studyComplex karyotypeHematopoietic stem cell transplantIntensive chemotherapy approachesYale Cancer CenterCharacteristics of patientsSingle-center experienceMinority of patientsStem cell transplantLong-term survivalLow response rateIntensive chemotherapyCenter experienceClinicopathologic characteristicsAdverse prognosisAML patientsCell transplantCardiotoxicity in Hematopoietic Stem Cell Transplant: Keeping the Beat
Baker JK, Shank-Coviello J, Zhou B, Dixon J, McCorkle R, Sarpong D, Medoff E, Cooper D, Seropian S, Dai F. Cardiotoxicity in Hematopoietic Stem Cell Transplant: Keeping the Beat. Clinical Lymphoma Myeloma & Leukemia 2020, 20: 244-251.e4. PMID: 32067953, DOI: 10.1016/j.clml.2019.12.027.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantCardiac eventsStem cell transplantCell transplantAtrial arrhythmiasAcute heart failureInstances of bradycardiaNew-onset hypertensionAcute coronary syndromeCoronary artery diseaseRisk of deathMultivariable regression analysisCoronary syndromeOnset hypertensionHSCT populationArtery diseaseHeart failureHSCT outcomesPericardial effusionAtrial dilationVentricular arrhythmiasSingle institutionSubgroup analysisBody of evidenceMedical history
2015
The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHD
Nadeau M, Perreault S, Seropian S, Foss F, Isufi I, Cooper DL. The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHD. Bone Marrow Transplantation 2015, 51: 273-276. PMID: 26479982, DOI: 10.1038/bmt.2015.247.Peer-Reviewed Original ResearchConceptsGastrointestinal acute GVHDAcute GVHDGrade IIIAllogeneic stem cell transplantCombination of basiliximabSevere GI GvHDSevere grade IIISteroid-refractory diseaseLong-term survivorsStem cell transplantOverall response rateCurrent retrospective studyChronic GVHDGI GVHDSalvage therapySteroid therapyPrimary diseaseCell transplantMedian timeSignificant morbidityPoor outcomeRetrospective studyGVHDMost deathsNew agents
2010
A Phase 1 Trial of Vorinostat and Pegylated Liposomal Doxorubicin In Relapsed or Refractory Lymphoma.
Lansigan F, Seropian S, Cooper D, Potter V, Sowers N, Foss F. A Phase 1 Trial of Vorinostat and Pegylated Liposomal Doxorubicin In Relapsed or Refractory Lymphoma. Blood 2010, 116: 2816. DOI: 10.1182/blood.v116.21.2816.2816.Peer-Reviewed Original ResearchDose level 3Stem cell transplantStable diseaseHL patientsHodgkin's lymphomaPartial responseRefractory lymphomaCell transplantCardiac toxicityDisease progressionLiposomal doxorubicinLymphoplasmacytic lymphomaGrade 3Prior treatmentAST/ALT elevationAutologous stem cell transplantMedian age 69 yearsAllogeneic stem cell transplantPeripheral T-cell lymphomaTherapy warrants further investigationDisease controlLarge B-cell lymphomaDose level 1Dose level 2Doses of vorinostat
1999
Neutropenic infections in 100 patients with non-Hodgkin’s lymphoma or Hodgkin’s disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option
Seropian S, Nadkarni R, Jillella A, Salloum E, Burtness B, Hu G, Zelterman D, Cooper D. Neutropenic infections in 100 patients with non-Hodgkin’s lymphoma or Hodgkin’s disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option. Bone Marrow Transplantation 1999, 23: 599-605. PMID: 10217191, DOI: 10.1038/sj.bmt.1701610.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmbulatory CareAntibiotic ProphylaxisAntineoplastic Combined Chemotherapy ProtocolsCarmustineCytarabineDose-Response Relationship, DrugHematopoietic Stem Cell TransplantationHodgkin DiseaseHumansLymphoma, Non-HodgkinMelphalanMiddle AgedNeutropeniaPodophyllotoxinRetrospective StudiesConceptsPeripheral blood progenitor cell transplantHigh-dose chemotherapyAbsolute neutrophil countProgenitor cell transplantCell transplantHodgkin's diseaseHodgkin's lymphomaHerpes simplex virus serologyHigh-dose BEAM chemotherapyGram-positive bacteremiaDuration of neutropeniaRisk of bacteremiaPeriod of neutropeniaMultivariate logistic regressionInvasive fungal infectionsRisk of developmentNumber of CD34Amphotericin therapyBEAM chemotherapyFebrile neutropeniaNeutropenic infectionOral ciprofloxacinWBC engraftmentProphylactic antibioticsCare visits